摘要
神经营养素是重要的神经营养因子,参与多种神经元群的存活、分化和功能。由蛋白水解而成的前体蛋白(神经营养因子的前体)合成是大部分神经营养因子的共同特点,使他们的营养功能呈现出激活形式。然而,这些蛋白的一些神经营养因子前体形式,如神经生长因子的前体 (pro-NGF),已经被显示通过 p75NTR 受体可以诱导其对神经元的相对立作用及触发其凋亡。这也意味着神经营养因子前体与神经营养因子之间的平衡必须严格控制。关于此点,处于像一些神经退行性疾病的老化或发展的氧化应激状态,神经营养因子至少能够被糖基化或脂质氧化终产物(AGE/ALEs)氧化修饰,而生成pro-NGF产物。缺乏成熟和倾向性失衡的先导形式也许会改变活化的细胞凋亡信号通路模式,因此恶化毒化过程,例如在神经退行性疾病发展期。 此外,AGE/ALEs 也可以诱导α分泌酶生成pro-NGF p75NTR受体的进程,其次是被γ分泌酶,且释放胞内区p75NTR (p75NTRICD)。一旦裂开,p75NTRICD会 募集两个胞内相互因子NRIF 和TRAF6, 它允许NPIR被JNK磷酸化。然后NRIF的磷酸化形式转移至细胞核,诱导凋亡蛋白前体表达。本文中,我们将会对哪些ROS诱导蛋白修饰、何种蛋白易受修饰影响、这些修饰是如何影响功能及他们如何与神经退行性疾病相关的机制进行总结。
关键词: 阿尔茨海默病,抗氧化剂,凋亡,神经退变,氧化应激,p75NTR,NGF前体
Current Drug Targets
Title:Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach
Volume: 16 Issue: 1
Author(s): Carme Espinet, Hugo Gonzalo, Catherine Fleitas, Maria Jose Menal and Joaquim Egea
Affiliation:
关键词: 阿尔茨海默病,抗氧化剂,凋亡,神经退变,氧化应激,p75NTR,NGF前体
摘要: Neurotrophins are important neurotrophic factors involved in the survival, differentiation and function of a wide variety of neuron populations. A common feature for most neurotrophins is that they are synthesized as precursor proteins (pro-neurotrophins) that upon being processed by proteolysis render the mature active form responsible for most of their trophic functions. However, some of the pro-neurotrophin form of these proteins, such as the precursor form of NGF (pro-NGF), have been shown to induce opposite effects and trigger apoptosis on neurons through the p75NTR receptor. This suggests that the balance between the levels of proneurotrophin and neurotrophin must be tightly controlled. In this context, it has been shown that in conditions of oxidative stress due for instance to aging or the development of some neurodegenerative disease, neurotrophins are oxidatively modified at least by advanced glycation/lipoxidation end products (AGE/ALEs) which makes pro-NGF refractary to be processed. The lack of maturation and the imbalance in favor of the precursor form may change the pattern of active signaling pathways towards cell death, thus exacerbating the deleterious alterations, for instance during the development of neurodegenerative diseases. Besides that, AGE/ALEs also induce the processing of the pro-NGF receptor p75NTR by α- secretase which is followed by the processing by γ -secretase and the release of the intracellular domain of p75NTR (p75NTRICD). Once cleaved, p75NTRICD recruits two intracellular interactors, NRIF and TRAF6, which allows NRIF phosphorylation by JNK. The phosphorylated form of NRIF then translocates to the nucleus and induces the expression of pro-apoptotic proteins. In this chapter we will summarize the mechanisms by which ROS- induce protein modifications, which proteins are susceptible to be modified, how these modifications affect function and signaling and, finally, how they can be related to neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Carme Espinet, Hugo Gonzalo, Catherine Fleitas, Maria Jose Menal and Joaquim Egea , Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach, Current Drug Targets 2015; 16 (1) . https://dx.doi.org/10.2174/1389450116666150107153233
DOI https://dx.doi.org/10.2174/1389450116666150107153233 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glutamate mGlu5-Adenosine A2A-Dopamine D2 Receptor Interactions in the Striatum. Implications for Drug Therapy in Neuro-psychiatric Disorders and Drug Abuse
Current Medicinal Chemistry - Central Nervous System Agents Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology Preclinical Data Supporting/Refuting the Use of Hypericum perforatum in the Treatment of Depression
CNS & Neurological Disorders - Drug Targets Conformational Changes of Prion Protein and Nucleic Acid Arising from their Interaction and Relation of the Altered Structures in Causing Prion Disease
Mini-Reviews in Medicinal Chemistry Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Transient Receptor Potential Canonical Channels for Diseases of the Nervous System
Current Drug Targets subject Index To Volume 2
Current Molecular Medicine Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
Current Pharmaceutical Design Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Current Drug Targets Antioxidant Capacities of Flavones and Benefits in Oxidative-Stress Related Diseases
Current Topics in Medicinal Chemistry Regional Differences in Adaptation of CNS Mu Opioid Receptors to Chronic Opioid Agonist Administration
Current Neuropharmacology Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells
Current Pharmaceutical Design Anti-Apoptotic Actions of Insulin-Like Growth Factors: Lessons from Development and Implications in Neoplastic Cell Transformation
Current Pharmaceutical Design Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design Angiogenesis and Metastasis Inhibitors for the Treatment of Malignant Melanoma
Mini-Reviews in Medicinal Chemistry Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Neuroglobin and Estrogen Receptors: A New Pathway of Cell Survival and Cell Death Balance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets